辽宁成大股份有限公司 关于股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至本公告披露日，辽宁成大股份有限公司（以下简称"公司"）股东广 西鑫益信商务服务有限公司（以下简称"广西鑫益信"）及其一致行动人共持有 公司股份 157,813,119 股，占公司总股本比例为 10.32%，累计质押公司股份数 量为 131,018,271 股（含本次），占其所持股份比例为 83.02%，占公司总股本比 例为 8.56%。 公司于 2024 年 5 月 22 日接到股东广西鑫益信函告，获悉其所持有的公司部 分股份被质押，具体事宜如下。 | | 是否 | | | 是否 | 质押 | 质押 | | 占其所 | 占公 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 为控 | 本次质押股 | 是否为 | | | | | | 司总 | 融资 | | | | | | 补充 | 起始 | 到期 | 质 ...

证券代码：600739 证券简称：辽宁成大 公告编号：临 2024-037 辽宁成大股份有限公司 关于召开 2023 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 5 月 24 日（星期五）14:00-15:00 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2024 年 5 月 17 日（星期五）至 5 月 23 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 liutong@chengda.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 辽宁成大股份有限公司（以下简称"公司"）已于 2024 年 4 月 27 日发布公 司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年度经营成 果、财务状况，公司计划于 ...

吉林敖东及其一致行动人合计持有公司股份 91,900,376 股，占公司总股本 的 6.0077%。 证券代码：600739 证券简称：辽宁成大 公告编号：临 2024－036 辽宁成大股份有限公司 关于股东增持计划完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次增持计划的基本情况：辽宁成大股份有限公司（以下简称"公司"） 股东吉林敖东药业集团股份有限公司（以下简称"吉林敖东"）计划自 2023 年 11 月 17 日起 6 个月内，以自有资金不低于人民币 1.1 亿元，不高于人民币 2.2 亿 元，通过上海证券交易所以集中竞价交易方式或大宗交易、协议转让等交易方式 增持公司 A 股普通股股票。具体内容详见公司于 2023 年 11 月 17 日披露的《辽 宁成大股份有限公司关于股东增持公司股份计划的公告》（公告编号：临 2023- 068）。 本次增持计划的实施情况：吉林敖东于 2023 年 11 月 17 日至 2024 年 5 月 16 日期间以自有资金 1.35 亿元，通过上海证券交易所 ...

Financial Performance - Total operating revenue for Q1 2024 reached ¥2,460,529,664.29, representing a 19.01% increase compared to ¥2,067,470,409.28 in Q1 2023[1] - Net profit for Q1 2024 was ¥63,758,817.96, a decrease of 79.1% compared to ¥305,943,174.87 in Q1 2023[32] - Basic earnings per share for Q1 2024 was ¥0.0578, reflecting a decrease of 70.97% year-over-year[6] - Operating profit for Q1 2024 was CNY 150,432,595.64, down 53.5% from CNY 323,622,445.54 in Q1 2023[52] - Net profit for Q1 2024 was CNY 149,802,313.31, a decrease of 53.7% compared to CNY 323,004,759.81 in Q1 2023[52] - The total comprehensive income for Q1 2024 was CNY 293,474,308.35, down from CNY 346,392,977.93 in Q1 2023[52] Cash Flow - The net cash flow from operating activities for Q1 2024 was negative at ¥356,953,308.79, indicating a significant cash outflow[6] - Cash inflow from operating activities for Q1 2024 was CNY 2,903,754,131.16, an increase of 17.7% compared to CNY 2,465,915,001.72 in Q1 2023[36] - Cash outflow from operating activities for Q1 2024 was CNY 3,260,707,439.95, up from CNY 2,851,500,425.41 in Q1 2023, resulting in a net cash flow of CNY -356,953,308.79[36] - The company's cash flow from operating activities showed a net outflow of CNY 442,916,350.55 in Q1 2024, compared to an outflow of CNY 458,162,389.93 in Q1 2023[55] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to ¥47,315,392,548.09, a slight increase of 0.88% from ¥46,900,699,100.93 at the end of the previous year[9] - Total liabilities increased to ¥15,500,399,591.96 from ¥15,277,444,416.41, marking a rise of 1.46%[27] - Total current assets as of March 31, 2024, were approximately ¥11.39 billion, compared to ¥11.37 billion at the end of 2023[18] - Total liabilities as of March 31, 2024, were CNY 13,982,575,866.92, slightly down from CNY 13,995,413,397.42 at the end of 2023[46] Shareholder Information - Total number of common shareholders at the end of the reporting period was 66,103[12] - The largest shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., holds 234,004,700 shares, accounting for 15.30% of total shares[12] - The shareholder structure indicates that the top two shareholders, Guangxi Xinyi Business Service Co., Ltd. and Guangxi Rongtuo Decoration Engineering Co., Ltd., are acting in concert[14] Investment and Expenses - Research and development expenses increased to ¥58,997,464.13, up from ¥44,378,770.68 in the same period last year[1] - Investment income for Q1 2024 was ¥244,029,332.11, a decrease from ¥436,469,217.04 in Q1 2023[1] - The company reported a decrease in investment income to CNY 241,684,153.13 in Q1 2024 from CNY 430,109,535.18 in Q1 2023, representing a decline of 43.9%[50] - The company incurred financial expenses of CNY 76,972,546.48 in Q1 2024, down from CNY 86,518,648.81 in Q1 2023[50] Other Financial Metrics - The weighted average return on equity for Q1 2024 was 0.30%, a decrease of 0.75 percentage points compared to the previous year[6] - Other comprehensive income after tax for Q1 2024 was ¥144,034,915.40, compared to ¥23,397,728.46 in Q1 2023, indicating a significant increase[32] - The total equity attributable to shareholders rose to ¥29,025,878,357.62 from ¥28,794,321,339.86, an increase of 0.80%[27] - The total non-current assets amounted to ¥35,921,333,222.05, up from ¥35,526,849,435.63, representing an increase of 1.11%[25]

证券代码：600739 证券简称：辽宁成大 公告编号：临 2024－029 辽宁成大股份有限公司 关于向广发证券股份有限公司购买理财产品 暨关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司拟使用自有阶段性闲置资金向关联方广发证券股份有限公司或其子 公司购买理财产品（包括公司子公司向广发证券股份有限公司或其子公司购买理 财产品）。 理财余额最高不超过人民币 12 亿元，单笔理财期限不超过 12 个月，此 理财额度可循环使用。 过去 12 个月内，公司（含子公司）与广发证券股份有限公司或其子公司 进行的交易累计金额为 9,000 万元。 过去 12 个月内，公司不存在向其他关联人购买理财的情况。 一、关联交易概述 1、关联交易的基本情况 （3）本次关联交易的程序安排符合法律、行政法规、部门规章及其他规范性 法律文件的规定，公开透明。 公司（含子公司）向广发证券或其子公司购买理财产品的关联交易事项符合 法律法规及公司内部规章制度的有关规定，不存在损害公司及其他股东利益的情 形，同意将该事项提交董事会 ...

RSM 容诚 内部控制审计报告 辽宁成大股份有限公司 容诚审字|2024|100Z0051 号 中国 ·北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查 c.mof.gov.cn) 进行 报告编码:京24A1K5G 容诚会计师事务所(特殊 骑 绝 草 内部控制审计报告 容诚会计师事务所 (特殊普通合伙) 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见。 我们认为,辽宁成大公司于 2023 年 12 月 31 日按照《企业内部控制基本规范》 和相关规定在所有重大方面保持了有效的财务报告内部控制。 容诚审字[2024]100Z0051 号 辽宁成大股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）董事会于 2024 年 4 月 15 日以 书面和电子邮件方式发出召开第十届董事会第二十五次会议的通知，会议于 2024 年 4 月 25 日在公司会议室以现场结合通讯方式召开并作出决议。公司董事 9 名， 出席会议董事 9 名。会议内容同时通知了公司监事。会议由董事长尚书志先生主 持。会议的召开符合《中华人民共和国公司法》和《公司章程》的有关规定。会 议审议并通过了以下事项： 证券代码：600739 证券简称：辽宁成大 公告编号：临 2024－025 辽宁成大股份有限公司 第十届董事会第二十五次会议决议公告 一、公司 2023 年度总裁业务报告 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 二、公司 2023 年度董事会工作报告 本议案尚需提交公司股东大会审议批准。 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 三、公司 2023 年年度报告全文及摘要（详见上海证券交易所网站） 本议案已经董事会审计委员会审议通 ...

公司代码：600739 公司简称：辽宁成大 辽宁成大股份有限公司 2023 年度内部控制评价报告 辽宁成大股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部 ...

第一条 为了促进辽宁成大股份有限公司（以下简称"公司"）提高资金使 用效益，防范和控制资金风险，保障资金安全，根据国家相关法律法规、《企业 内部控制基本规范》和《企业内部控制应用指引第 6 号—资金活动》，结合公司 实际，制订本制度。 第二条 本制度所称的货币资金是指公司拥有的现金、银行存款和其他货币 资金等。本制度的货币资金管理包含筹资、资金集中与收付、资金账户等与资金 活动相关的管理。货币资金管理至少须防范以下风险： （一）筹资决策不当，引发资本结构不合理或无效融资，可能导致企业筹 资成本过高或债务危机； （二）资金调度不合理、营运不畅，可能导致企业陷入财务困境或资金冗 余； 辽宁成大股份有限公司 货币资金管理制度 第一章 总则 （三）资金活动管控不严，可能导致资金被挪用、侵占、抽逃或遭受欺诈。 第三条 资金管理的原则 （一）集中管控原则。公司及控股子公司（以下简称"子公司"）筹资活动、 投资活动、经营活动产生的货币资金收支，由公司统一规划、统筹安排、集中管 控。 （二）战略导向原则。公司资金管理必须与整体发展战略保持一致，以支持 战略规划的实现。 （三）风险可控原则。公司及子公司要充分重视资金使用的风险 ...

Financial Performance - Xinjiang Baoming's net profit decreased by 547 million yuan, a decline of 73.76% due to increased operating losses and long-term asset impairment [8]. - Chengda Bio's net profit fell by 248 million yuan, a decrease of 34.75% attributed to a slight decline in revenue and rising costs [8]. - Guangfa Securities reported a net profit decline of 1.035 billion yuan, a drop of 11.63% [8]. - China Insurance's net profit decreased by 583 million yuan, a decline of 77.57% [8]. - The company's total revenue for the year was approximately ¥10.62 billion, a decrease of 26.26% compared to the previous year [30]. - The company's total operating revenue was approximately 10.783 billion RMB, down 25.97% from 14.565 billion RMB in the previous year [50]. - The net profit attributable to shareholders was 233 million RMB, down 80.95% year-on-year [58]. - The investment income from Guangfa Securities was 1.129 billion RMB, a decline of 18.61% compared to the previous year [59]. - The investment income from China Insurance was 17 million RMB, down 86.53% year-on-year [59]. - The company's operating cash flow net amount was 119.71 million RMB, a decrease of 91.61% compared to 1.427 billion RMB in the previous year [50]. - The basic earnings per share for 2023 is 0.1530 CNY, a decrease of 80.90% compared to 0.8010 CNY in 2022 [88]. - The net profit attributable to shareholders of the listed company for 2023 is -365,046,465.98 CNY, showing a significant decline from the previous year's profit [90]. - The operating cash flow for 2023 is -385,585,423.69 CNY, indicating a decrease in cash inflow compared to the previous year [90]. - The company's operating revenue for 2023 was approximately RMB 10.78 billion, a decrease of 25.97% compared to RMB 14.56 billion in 2022 [107]. - The net cash flow from operating activities was approximately RMB 119.71 million, a decline of 91.61% compared to RMB 1.43 billion in 2022 [107]. - The total assets at the end of 2023 were approximately RMB 46.90 billion, a decrease of 2.59% from RMB 48.15 billion at the end of 2022 [107]. - The net cash flow from investing activities turned negative at -¥970,077,846.41, a decline of 129.27% compared to ¥3,314,586,458.66 last year [161]. Industry Trends - The overall industry trend indicates a slight growth in insurance premium income, but continued pressure on the investment side, making profit growth challenging for insurance companies [9]. - The global economic growth rate is slowing down, with rising inflation in major economies and declining overseas market demand [15]. - The supply chain service industry is highly competitive, with expectations of gradual recovery in the domestic steel industry, while coal and grain market demand remains weak [17]. - The insurance industry saw a premium income growth of 9.1% year-on-year, with total original premium income reaching 5.1 trillion yuan [136]. - The vaccine industry is characterized by high barriers to entry, requiring substantial investment and long-term commitment to R&D [184]. - The global human vaccine market is dominated by four multinational pharmaceutical companies: Merck, GlaxoSmithKline, Sanofi, and Pfizer, which collectively hold over 80% market share [200]. - From 2021 to 2025, the global human vaccine market size is projected to grow from $46 billion to $83.1 billion, representing a compound annual growth rate (CAGR) of approximately 12.5% [200]. Operational Challenges - The company faced a complex operating environment in 2023, with challenges including geopolitical conflicts and a slowdown in international trade [95]. - The company has identified multiple risks and challenges in its operational environment, which are detailed in the management discussion section [99]. - The company reported a decrease in investment income from joint ventures, contributing to the decline in net profit [89]. Strategic Initiatives - The company aims to strengthen its core capabilities in the biopharmaceutical sector while seeking breakthroughs in the medical and healthcare industry chain [10]. - The company is deepening strategic cooperation with Guangfa Securities and China Insurance to enhance financial support for its industrial operations [10]. - The company is focusing on enhancing the sales team and expanding market coverage to maintain its leading position in the human rabies vaccine market [45]. - The company is actively improving its quality management system and drug vigilance system to mitigate potential risks related to product safety [45]. - The company is exploring partnerships with external research institutions and biotech companies to develop innovative vaccine products [45]. - The company is committed to optimizing its national marketing network to effectively increase its domestic market share [45]. - The company is focusing on the development of new vaccine technologies and expanding its product offerings in the biopharmaceutical sector [54]. - The company aims to enhance its dual-driven development strategy in the pharmaceutical and financial investment sectors [95]. Production and Sales - The pharmaceutical segment achieved sales revenue of 1.751 billion RMB, a year-on-year decrease of 3.60%, and a net profit of 466 million RMB, down 34.67% [45]. - The supply chain service (trade) segment reported sales revenue of 8.549 billion RMB, a year-on-year decline of 25.60%, with a net profit of 7.4 million RMB, down 81.65% [48]. - The energy development segment generated sales revenue of 471 million RMB, a year-on-year decrease of 62.20%, resulting in a net loss of 1.288 billion RMB, significantly increasing the loss compared to the previous year [49]. - Revenue from import and export trade declined primarily due to a decrease in the scale of medical supplies exports [30]. - The company's shale oil production is primarily sold in Xinjiang, with a significant decrease in production volume by 71.28% year-on-year [153]. - The production volume of human rabies vaccines reached 24,689,873 units, while sales volume was 24,471,122 units, reflecting a production increase of 27.98% but a sales decrease of 9.71% year-on-year [153]. - The production of inactivated encephalitis vaccines decreased by 53.63% due to adjustments in production plans, while sales increased by 64.52% due to expanded marketing efforts [155]. Research and Development - Research and development expenses increased by 4.26% to 220.46 million RMB from 211.46 million RMB in the previous year [50]. - The company has developed four major R&D technology platforms for vaccines, with over 20 vaccine products under research, including human rabies vaccines and quadrivalent influenza vaccines currently in phase III clinical trials [122]. - Total R&D investment reached 418,515,690.47 RMB, which is 3.88% of the operating revenue [174]. - Capitalized R&D investment constituted 47.32% of the total R&D investment [174]. - The company has 201 R&D personnel, accounting for 5.99% of the total workforce, with 12 holding doctoral degrees [160]. - The company has a total of 418 R&D personnel, with 54 under 30 years old and 91 between 30-40 years old [190].